Pharmesis International (SGX:BFK) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:BFK Pharmesis International Ltd SGX:BFK
34 GF Score
Price S$0.13
GF Value S$0.16
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Pharmesis International FFO per Share?

FFO per Share only applies to REITs.

SGX:BFK
34GF Score
Pharmesis International Ltd SGX:BFK
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharmesis International (SGX:BFK) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmesis International stock appears to be undervalued. The current stock price of S$0.13 is trading 21.9% below its estimated GF Value™ of S$0.16. GuruFocus considers Pharmesis International to be Modestly Undervalued.

Key valuation signals for SGX:BFK:

  • FFO per Share:
  • GF Value™: S$0.16 vs. price of S$0.13 (21.9% below fair value)
  • GF Score™: 34/100 with 6 warning signs

No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmesis International Business Description

Address 5 Kallang Sector, No. 03-02, Singapore, SGP, 349279
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
34GF Score

Get the complete analysis for SGX:BFK

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.13
Price
S$0.16
GF Value